Melanoma Research最新文献_第2页

Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case report. 可切除黑色素瘤辅助抗pd -1治疗后发生类固醇难治性严重免疫相关性粘膜炎1例报告

IF 1.9 4区医学

Melanoma Research Pub Date : 2025-10-01 Epub Date: 2025-04-01 DOI: 10.1097/CMR.0000000000001037

Sidsel Pedersen, Troels Holz Borch, Inge Marie Svane, Marco Donia, Eva Ellebaek

{"title":"Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case report.","authors":"Sidsel Pedersen, Troels Holz Borch, Inge Marie Svane, Marco Donia, Eva Ellebaek","doi":"10.1097/CMR.0000000000001037","DOIUrl":"10.1097/CMR.0000000000001037","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and are increasingly used, also in the adjuvant and neoadjuvant settings. ICIs, however, can induce immune-related adverse events (irAEs), which range from mild to life-threatening. As the use of ICIs expands, prompt identification and management of especially severe and life-threatening irAEs are crucial. We report a case of grade 4 steroid-refractory immune-related mucositis in a 60-year-old male treated with pembrolizumab following complete resection of stage IIIC melanoma. The patient received seven courses of adjuvant pembrolizumab without adverse events until 2 weeks after the seventh dose, when he presented with acute respiratory distress, dysphagia, and dyspnea. Examination revealed significant throat swelling and mucosal edema. Despite initial treatment with high-dose steroids, the patient's condition deteriorated, and he was admitted to the ICU for intubation and close monitoring. Infliximab was administered for steroid-refractory mucositis, resulting in rapid symptom resolution and successful extubation 5 days later. This case highlights the challenges in managing severe steroid-refractory irAEs. The rapid response to infliximab suggests the benefit of early intervention with alternative immunosuppressive agents in severe irAEs. Increased awareness of rare irAEs is essential for optimizing treatment and improving outcomes for patients receiving ICIs.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"344-346"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful use of nivolumab and relatlimab as salvage therapy for metastatic uveal melanoma. 成功使用纳武单抗和relatlimab作为转移性葡萄膜黑色素瘤的挽救性治疗。

IF 1.9 4区医学

Melanoma Research Pub Date : 2025-10-01 Epub Date: 2025-05-27 DOI: 10.1097/CMR.0000000000001045

Ritwick S Mynam, Nandakumar Menon, Alexander Birbrair, Vincent T Ma

引用次数: 0

Literature case analysis of immune checkpoint inhibitors-associated lipodystrophy. 免疫检查点抑制剂与脂肪营养不良相关的文献病例分析。

IF 1.9 4区医学

Melanoma Research Pub Date : 2025-10-01 Epub Date: 2025-07-01 DOI: 10.1097/CMR.0000000000001053

Zhen Zhao, Yuqiu Yang, Yunhong Zou, Wen Zhang

{"title":"Literature case analysis of immune checkpoint inhibitors-associated lipodystrophy.","authors":"Zhen Zhao, Yuqiu Yang, Yunhong Zou, Wen Zhang","doi":"10.1097/CMR.0000000000001053","DOIUrl":"10.1097/CMR.0000000000001053","url":null,"abstract":"The objective of this study was to investigate the clinical characteristics of lipodystrophy induced by immune checkpoint inhibitors (ICIs). Domestic and international databases were searched as of 28 February 2025 and case reports of ICI-associated lipodystrophy were collected. Relevant information including patients' basic information, ICI application, the occurrence of lipodystrophy, etc., were extracted and descriptively analyzed. A total of 11 patients were included in the analysis, including two males and nine females, age from 34 to 76 years, with an average age of 55 years. The primary diseases were mainly lung cancer, melanoma and renal cell carcinoma. The latency period from ICI initiation to lipodystrophy diagnosis ranged from 42 to 540 days. Clinical manifestations included facial fat pad depletion and subcutaneous fat loss in trunk and extremities. Treatment regimens included pembrolizumab ( n = 3), nivolumab ( n = 6), cadonilimab ( n = 1), and nivolumab/ipilimumab combination ( n = 1). Serum leptin levels were tested in seven patients, and two had serum leptin concentrations <0.5 ng/ml, the others ranged from 0.6 to 61.1 ng/ml. Eight cases had records of glycated hemoglobin testing, of which five cases had glycated hemoglobin ≥6.5%. After being diagnosed with lipodystrophy, seven patients discontinued ICIs while four continued treatment. Four patients received steroid therapy and seven cases had no relevant records. Among the 11 patients, only one patient demonstrated subcutaneous fat improvement, and seven patients' prognosis was not reported. None of the eight patients who discontinued treatment resumed immunotherapy. ICI-associated lipodystrophy presents similar clinical features to conventional lipodystrophy but shows limited reversibility with treatment cessation or steroid intervention, necessitating increased clinical awareness.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"300-305"},"PeriodicalIF":1.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contralateral axillary sentinel lymph node in chest wall melanoma: first documented case and narrative review of the literature. 胸壁黑色素瘤对侧腋窝前哨淋巴结：第一例文献记录和文献回顾。

IF 1.9 4区医学

Melanoma Research Pub Date : 2025-09-26 DOI: 10.1097/CMR.0000000000001065

Luke Davies, Vasileios Skepastianos, Chrysoula Palazi, Georgios Skepastianos

{"title":"Contralateral axillary sentinel lymph node in chest wall melanoma: first documented case and narrative review of the literature.","authors":"Luke Davies, Vasileios Skepastianos, Chrysoula Palazi, Georgios Skepastianos","doi":"10.1097/CMR.0000000000001065","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001065","url":null,"abstract":"This case report and literature review detail and contextualise the finding of a positive sentinel node in the contralateral axilla of a 69-year-old male with cutaneous malignant melanoma of the left chest wall. Excision biopsy confirmed nodular melanoma (Breslow thickness 6.6 mm; mitotic index 11; no ulceration or microsatellites; completely excised; pT4a). Preoperative lymphoscintigraphy identified the sentinel node in the right axilla. The patient underwent wide local excision with 2-cm margins and a sentinel lymph node biopsy, which showed no spread of disease. This was followed by six cycles of adjuvant pembrolizumab with surveillance scans remaining clear. Literature review identified 22 cases of anterior chest wall melanoma (n = 4) or breast carcinoma (n = 18) with contralateral drainage (12 case reports, two case series, and eight retrospective studies). Only one previous chest wall melanoma case with contralateral drainage was identified, but details were not reported. Thus, we present the first documented case of anterior chest wall melanoma with a contralateral sentinel node, and emphasise the importance of thorough evaluation of suspicious lesions for unexpected drainage patterns.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145150027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Late peritoneal carcinomatosis from cutaneous melanoma mimicking ovarian cancer. 模仿卵巢癌的皮肤黑色素瘤引起的晚期腹膜癌。

IF 1.9 4区医学

Melanoma Research Pub Date : 2025-09-10 DOI: 10.1097/CMR.0000000000001064

Stefano Fucina, Lucia Lerda, Anna Del Fabro, Claudio Reato, Emilio Lucia, Nicolò Clemente, Fabio Puglisi, Michele Bartoletti, Antonio Palumbo, Vincenzo Canzonieri, Antonino Ditto

{"title":"Late peritoneal carcinomatosis from cutaneous melanoma mimicking ovarian cancer.","authors":"Stefano Fucina, Lucia Lerda, Anna Del Fabro, Claudio Reato, Emilio Lucia, Nicolò Clemente, Fabio Puglisi, Michele Bartoletti, Antonio Palumbo, Vincenzo Canzonieri, Antonino Ditto","doi":"10.1097/CMR.0000000000001064","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001064","url":null,"abstract":"Peritoneal carcinomatosis represents an exceptionally rare metastatic pattern of cutaneous malignant melanoma, occurring in fewer than 1% of cases with distant spread and typically within the first few years after primary treatment. This report presents an unusual case with a markedly prolonged disease-free interval, clinically mimicking advanced ovarian carcinoma. We report the case of a 53-year-old woman treated more than 10 years ago for stage IIB nodular melanoma with surgery and adjuvant therapy. The patient presented with progressive abdominal bloating. Imaging revealed bilateral adnexal masses, ascites, peritoneal carcinomatosis, and multiple pulmonary nodules, initially suggestive of advanced ovarian cancer. Diagnostic laparoscopy demonstrated diffuse peritoneal lesions with an atypical yellowish, soft, and nonpigmented appearance. Histology and immunohistochemistry confirmed metastatic melanoma. This case is among the few reports of peritoneal carcinomatosis from melanoma after more than a decade of remission. The prolonged disease-free interval and atypical presentation underline the heterogeneous behavior of melanoma and the need for long-term vigilance and multidisciplinary evaluation.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study. 西班牙晚期粘膜黑色素瘤患者的治疗结果：来自真实世界GEM1801研究的结果

IF 1.9 4区医学

Melanoma Research Pub Date : 2025-09-03 DOI: 10.1097/CMR.0000000000001062

Pablo Cerezuela-Fuentes, Carlos Aguado de la Rosa, Guillermo Crespo, Miguel-Ángel Berciano-Guerrero, Ainara Soria, Eva Muñoz-Couselo, Rafael López Castro, Margarita Majem, Pablo Ayala de Miguel, José Luis Manzano, Lorena Bellido, M José Lecumberri, Mónica Corral Subias, José Carlos Villa Guzmán, Berta Hernández, Enrique Espinosa, Teresa Puértolas, Lourdes Gutiérrez Sanz, Javier Medina Martínez, Vicente Palomar Abril, Salvador Martín Algarra, Iván Márquez-Rodas

{"title":"Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study.","authors":"Pablo Cerezuela-Fuentes, Carlos Aguado de la Rosa, Guillermo Crespo, Miguel-Ángel Berciano-Guerrero, Ainara Soria, Eva Muñoz-Couselo, Rafael López Castro, Margarita Majem, Pablo Ayala de Miguel, José Luis Manzano, Lorena Bellido, M José Lecumberri, Mónica Corral Subias, José Carlos Villa Guzmán, Berta Hernández, Enrique Espinosa, Teresa Puértolas, Lourdes Gutiérrez Sanz, Javier Medina Martínez, Vicente Palomar Abril, Salvador Martín Algarra, Iván Márquez-Rodas","doi":"10.1097/CMR.0000000000001062","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001062","url":null,"abstract":"Patients with mucosal melanoma have lower survival rates than those with cutaneous melanoma. Recent studies have reported lower mucosal melanoma survival rates with the use of immune checkpoint inhibitors (ICIs). This study analyzed ICI treatment outcomes in patients with mucosal melanoma in a real-world context. The objective response rate, progression-free survival (PFS), and overall survival (OS) after first- and second-line ICI treatments were analyzed in a population of patients with advanced mucosal melanoma included in the observational GEM1801 study in Spain. Univariate Cox regression analysis was used to identify prognostic factors. From 1126 patients included between August 2018 and January 2024, 52 (4.6%) patients with mucosal melanoma were selected, with a median age at advanced stage diagnosis of 70 years; 50% were female. Most patients had an Eastern Cooperative Oncology Group performance status of 0 (48%). Tumors were primarily located in the lower gastrointestinal tract (40%) and the nasal cavity (35%). In the metastatic setting, 32 (62%) patients received ICI. At a median follow-up of 13.7 months, patients receiving ICI had a median PFS and OS of 9.4 [95% confidence interval (CI): 6.6-17.0] and 25.9 (95% CI: 21-not reached) months, respectively, for first-line treatment, and 5.1 (95% CI: 1.9-not reached) and 21.0 (95% CI: 11.1-not reached) months for second-line treatment. The clinical benefit of ICI treatment in mucosal melanoma is in accordance with previous clinical trials but is still limited, highlighting the need for new approaches for this patient population.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144993198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A high range of intrinsic disorder values for tumor resident, T-cell receptor beta V-complementarity determining region 3-J amino acid sequence assemblies correlates with better melanoma outcomes. 肿瘤驻留的高范围内在紊乱值，t细胞受体β v -互补决定区域3-J氨基酸序列组装与更好的黑色素瘤预后相关。

IF 1.9 4区医学

Melanoma Research Pub Date : 2025-08-29 DOI: 10.1097/CMR.0000000000001061

Joyce J Zhu, Arpan Sahoo, Joanna J Song, Veda Naga Priya Vangala, Utsav Kapoor, George Blanck

{"title":"A high range of intrinsic disorder values for tumor resident, T-cell receptor beta V-complementarity determining region 3-J amino acid sequence assemblies correlates with better melanoma outcomes.","authors":"Joyce J Zhu, Arpan Sahoo, Joanna J Song, Veda Naga Priya Vangala, Utsav Kapoor, George Blanck","doi":"10.1097/CMR.0000000000001061","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001061","url":null,"abstract":"Metastatic melanoma is characterized by high rates of treatment resistance. While various factors have been studied for their prognostic significance, this study evaluated the potential prognostic value of the intrinsic disorder of T-cell receptor beta (TRB) polypeptides. TRB recombination sequencing reads were extracted from tumor RNA-seq files representing The Cancer Genome Atlas, Skin Cutaneous Melanoma dataset, and genomics files representing the National Institutes of Health, phs002683 dataset. Intrinsic disorder values were computed for the TRB V-complementarity determining region 3 (CDR3)-J amino acid sequences for all cases. Survival analyses assessed overall survival and disease-specific survival for case sets based on assigning cases to upper or lower 50th percentile groups, based in turn on intrinsic disorder values. For the phs002683 dataset, intrinsic disorder values were compared between cases representing resistance to immune checkpoint inhibitors (ICIs) and cases representing no observed resistance. The results indicated that the upper 50th percentile of the range of intrinsic disorder values was linked to better outcomes. This was obtained for two TRB datasets representing different RNA-seq file, recombination read extraction algorithms, and was observed for two different intrinsic disorder models. Furthermore, low minimum various long-3 and various short-long 2 values correlated with ICI treatment resistance. The findings of this study suggest that the diversity of intrinsic disorder values representing TRB V-CDR3-J assemblies may represent a novel prognostic biomarker for metastatic melanoma cases and a potential biomarker for indicating different personalized treatments.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating neutrophils, lymphocytes and eosinophils: development and validation of the NLE Index in ICI-treated metastatic melanoma. 整合中性粒细胞、淋巴细胞和嗜酸性粒细胞：ci治疗的转移性黑色素瘤NLE指数的发展和验证。

IF 1.9 4区医学

Melanoma Research Pub Date : 2025-08-29 DOI: 10.1097/CMR.0000000000001060

Fatma Pinar Açar, Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, Bilge Bayir, Irem Özdemir, Tuğba Mermer, Burçak Karaca

{"title":"Integrating neutrophils, lymphocytes and eosinophils: development and validation of the NLE Index in ICI-treated metastatic melanoma.","authors":"Fatma Pinar Açar, Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, Bilge Bayir, Irem Özdemir, Tuğba Mermer, Burçak Karaca","doi":"10.1097/CMR.0000000000001060","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001060","url":null,"abstract":"Prognosis for metastatic melanoma patients treated with immune checkpoint inhibitors (ICIs) remains heterogeneous. Although neutrophil-to-lymphocyte ratio (NLR) and neutrophil-to-eosinophil ratio (NER) are established markers, we hypothesized a neutrophil-to-lymphocyte-times-eosinophil (NLE) index would offer superior stratification. We analyzed 194 metastatic melanoma patients receiving ICIs, divided into training (n = 129) and validation (n = 65) cohorts. An optimal NLE cutoff categorized patients as NLE-low or NLE-high. Survival outcomes and objective response rate (ORR) were assessed using Kaplan-Meier, Cox regression, and logistic regression. Predictive accuracy of NLE, NLR, and NER was compared. Median overall survival was significantly longer in NLE-low versus NLE-high patients (training: 31.3 versus 6.9 months; P = 0.011; validation: 33.5 versus 9.1 months; P = 0.019). Median progression-free survival also improved significantly in NLE-low patients (training: 10.6 versus 3.1 months; P = 0.029; validation: 13.7 versus 3.9 months; P = 0.012). ORR was higher in NLE-low groups (training: 46.0% versus 13.2%; P < 0.001; validation: 43.6% versus 18.2%; P = 0.078). NLE demonstrated superior predictive accuracy compared with NLR and NER. The NLE index outperforms NLR and NER in predicting survival and response in metastatic melanoma patients treated with ICIs, providing a practical clinical tool.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment and survival disparities in acral lentiginous melanoma: a National Cancer Database multivariate analysis. 肢端黄斑性黑色素瘤的治疗和生存差异：国家癌症数据库的多变量分析。

IF 1.9 4区医学

Melanoma Research Pub Date : 2025-08-05 DOI: 10.1097/CMR.0000000000001059

Rachel C Chang, Elise K Brunsgaard, David C Reid

{"title":"Treatment and survival disparities in acral lentiginous melanoma: a National Cancer Database multivariate analysis.","authors":"Rachel C Chang, Elise K Brunsgaard, David C Reid","doi":"10.1097/CMR.0000000000001059","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001059","url":null,"abstract":"This retrospective cohort study evaluated disparities across insurance types, racial groups, and socioeconomic status (SES) in acral lentiginous melanoma (ALM). We analyzed adults diagnosed with ALM in the National Cancer Database from 2016-2020. Cox proportional hazards model assessed associations between demographic and clinical variables with ALM-specific survival. Kaplan-Meier curves analyzed 1-, 3-, and 5-year survival. A total of 3446 patients with ALM were identified. Uninsured patients presented with advanced-stage cancers, experienced longer time to treatment, and were more likely to undergo major amputations compared with privately insured patients (P < 0.001). Survival analysis indicated lower probabilities for uninsured patients at 1, 3, and 5 years, although the differences did not reach statistical significance. Black patients were more likely uninsured, had higher Charlson-Deyo comorbidity scores, resided in areas of lower income and education, experienced longer time to treatment (P < 0.001), and had significantly lower survival at 3 and 5 years compared with White patients (P < 0.01). Patients in SES Q1 traveled further for care, had longer time to treatment, were less likely to be treated with Mohs surgery (P < 0.001), and had worse survival at 1, 3, and 5 years compared with patients in SES Q4 (P < 0.001). In conclusion, significant disparities in disease presentation, access to care, and health outcomes in patients with ALM exist based on insurance status, race, and SES, emphasizing the need for targeted interventions to enhance early diagnosis and equitable treatment.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nomograms versus artificial intelligence platforms: which one can better predict sentinel node positivity in melanoma patients? nomograph与人工智能平台：哪一个能更好地预测黑色素瘤患者前哨淋巴结阳性？

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-08-01 Epub Date: 2025-05-27 DOI: 10.1097/CMR.0000000000001047

Eduardo Bertolli, Sara B Micheletti, Veridiana P de Camargo, Tiago V da Silva, Carlos E Bacchi, Antonio C Buzaid

{"title":"Nomograms versus artificial intelligence platforms: which one can better predict sentinel node positivity in melanoma patients?","authors":"Eduardo Bertolli, Sara B Micheletti, Veridiana P de Camargo, Tiago V da Silva, Carlos E Bacchi, Antonio C Buzaid","doi":"10.1097/CMR.0000000000001047","DOIUrl":"10.1097/CMR.0000000000001047","url":null,"abstract":"Nomograms are commonly used in oncology to assist clinicians in individualized decision-making processes, such as considering sentinel node biopsy (SNB) for melanoma patients. Concurrently, artificial intelligence (AI) is increasingly being utilized in medical predictions. This study aims to compare the predictive accuracy of nomograms and AI platforms for SNB positivity in a real-world cohort of melanoma patients. A retrospective analysis of melanoma patients who underwent SNB from 2020 to 2024 in a single institution was performed. Three open-access nomograms and three public AI platforms were employed to assess SNB positivity based on comprehensive clinical and pathological characteristics. Our cohort comprised 62 melanoma patients who have undergone SNB, of whom 12 (19.4%) were positive. There was no concordance among the three nomograms, nor among AI platforms ( P < 0.001). Only the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram scored statistically different between positive and negative SNB ( P = 0.04), and ChatGPT was the only AI platform that was also statistically significant ( P = 0.02). Only ChatGPT score was statistically significant for SNB positivity after univariate logistic regression (odds ratio: 1.05; 95% confidence interval: 1.004-1.108; P = 0.03). A receiver operating characteristic curve based on ChatGPT predictions generated a model with an area under the curve (AUC) of 0.702. Integrating MSKCC predictions marginally improved the model's predictive performance, enhancing the AUC to 0.715. In conclusion, SNB positivity could be better performed by an AI platform in this cohort of patients. Enhancing AI platforms could provide better populations for nomogram validation, which would lead to better predictive models.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"227-231"},"PeriodicalIF":1.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0